{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T11:42:29Z","timestamp":1770291749097,"version":"3.49.0"},"reference-count":82,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2020,12,13]],"date-time":"2020-12-13T00:00:00Z","timestamp":1607817600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"H.W. &amp; J. Hector Foundation","award":["M80"],"award-info":[{"award-number":["M80"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>In the absence of an active prophylactic vaccine against HIV-1, passively administered, broadly neutralizing antibodies (bnAbs) identified in some chronically infected persons were shown to prevent HIV-1 infection in animal models. However, passive administration of bnAbs may not be suited to prevent sexual HIV-1 transmission in high-risk cohorts, as a continuous high level of active bnAbs may be difficult to achieve at the primary site of sexual transmission, the human vagina with its acidic pH. Therefore, we used Lactobacillus, a natural commensal in the healthy vaginal microbiome, to express bn nanobodies (VHH) against HIV-1 that we reported previously. After demonstrating that recombinant VHHA6 expressed in E. coli was able to protect humanized mice from mucosal infection by HIV-1Bal, we expressed VHHA6 in a soluble or in a cell-wall-anchored form in Lactobacillus rhamnosus DSM14870. This strain is already clinically applied for treatment of bacterial vaginosis. Both forms of VHHA6 neutralized a set of primary epidemiologically relevant HIV-1 strains in vitro. Furthermore, VHHA6 was still active at an acidic pH. Thus, lactobacilli expressing bn VHH potentially represent an attractive vector for the passive immunization of women in cohorts at high risk of HIV-1 transmission.<\/jats:p>","DOI":"10.3390\/vaccines8040758","type":"journal-article","created":{"date-parts":[[2020,12,13]],"date-time":"2020-12-13T23:39:36Z","timestamp":1607902776000},"page":"758","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Lactobacilli Expressing Broadly Neutralizing Nanobodies against HIV-1 as Potential Vectors for HIV-1 Prophylaxis?"],"prefix":"10.3390","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7742-8879","authenticated-orcid":false,"given":"Sarah","family":"Kalusche","sequence":"first","affiliation":[{"name":"Georg-Speyer-Haus, Paul-Ehrlich-Stra\u00dfe 42-44, 60596 Frankfurt, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4552-9170","authenticated-orcid":false,"given":"Kanika","family":"Vanshylla","sequence":"additional","affiliation":[{"name":"Laboratory of Experimental Immunology, Institute of Virology, Faculty of Medicine and University Hospital Cologne, University of Cologne, 50931 Cologne, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franziska","family":"Kleipass","sequence":"additional","affiliation":[{"name":"Laboratory of Experimental Immunology, Institute of Virology, Faculty of Medicine and University Hospital Cologne, University of Cologne, 50931 Cologne, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0725-7138","authenticated-orcid":false,"given":"Henning","family":"Gruell","sequence":"additional","affiliation":[{"name":"Laboratory of Experimental Immunology, Institute of Virology, Faculty of Medicine and University Hospital Cologne, University of Cologne, 50931 Cologne, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5726-5585","authenticated-orcid":false,"given":"Barbara","family":"M\u00fcller","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Virology Centre for Integrative Infectious Diseases Research (CIID), University Hospital Heidelberg, 69120 Heidelberg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhu","family":"Zeng","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Division of Clinical Immunology and Transfusion Medicine, Karolinska Institutet at Karolinska University Hospital Huddinge, 14186 Stockholm, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathrin","family":"Koch","sequence":"additional","affiliation":[{"name":"Georg-Speyer-Haus, Paul-Ehrlich-Stra\u00dfe 42-44, 60596 Frankfurt, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1473-9706","authenticated-orcid":false,"given":"Stefan","family":"Stein","sequence":"additional","affiliation":[{"name":"Georg-Speyer-Haus, Paul-Ehrlich-Stra\u00dfe 42-44, 60596 Frankfurt, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7168-349X","authenticated-orcid":false,"given":"Harold","family":"Marcotte","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Division of Clinical Immunology and Transfusion Medicine, Karolinska Institutet at Karolinska University Hospital Huddinge, 14186 Stockholm, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1376-1792","authenticated-orcid":false,"given":"Florian","family":"Klein","sequence":"additional","affiliation":[{"name":"Laboratory of Experimental Immunology, Institute of Virology, Faculty of Medicine and University Hospital Cologne, University of Cologne, 50931 Cologne, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2491-4758","authenticated-orcid":false,"given":"Ursula","family":"Dietrich","sequence":"additional","affiliation":[{"name":"Georg-Speyer-Haus, Paul-Ehrlich-Stra\u00dfe 42-44, 60596 Frankfurt, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2020,12,13]]},"reference":[{"key":"ref_1","unstructured":"(2020, November 10). UNAIDS Fact Sheet. Available online: https:\/\/www.unaids.org\/en\/resources\/fact-sheet."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1056\/NEJMe1207438","article-title":"Preexposure prophylaxis for HIV--where do we go from here?","volume":"367","author":"Cohen","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1146\/annurev-immunol-080219-023629","article-title":"Vaccines and Broadly Neutralizing Antibodies for HIV-1 Prevention","volume":"38","author":"Stephenson","year":"2020","journal-title":"Annu. Rev. Immunol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1056\/NEJMoa1608243","article-title":"Effect of HIV Antibody VRC01 on Viral Rebound after Treatment Interruption","volume":"375","author":"Bar","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/nature14411","article-title":"Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117","volume":"522","author":"Caskey","year":"2015","journal-title":"Nature"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/nm.4268","article-title":"Antibody 10-1074 suppresses viremia in HIV-1-infected individuals","volume":"23","author":"Caskey","year":"2017","journal-title":"Nat. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/nature17677","article-title":"A single injection of anti-HIV-1 antibodies protects against repeated SHIV challenges","volume":"533","author":"Gautam","year":"2016","journal-title":"Nature"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"4201","DOI":"10.1128\/JVI.03608-14","article-title":"HIV-1 fitness cost associated with escape from the VRC01 class of CD4 binding site neutralizing antibodies","volume":"89","author":"Lynch","year":"2015","journal-title":"J. Virol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"18921","DOI":"10.1073\/pnas.1214785109","article-title":"Highly potent HIV-specific antibody neutralization in vitro translates into effective protection against mucosal SHIV challenge in vivo","volume":"109","author":"Moldt","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/nature18929","article-title":"HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption","volume":"535","author":"Scheid","year":"2016","journal-title":"Nature"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.cell.2020.01.010","article-title":"Restriction of HIV-1 Escape by a Highly Broad and Potent Neutralizing Antibody","volume":"180","author":"Schommers","year":"2020","journal-title":"Cell"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1038\/s41590-018-0235-7","article-title":"Recent progress in broadly neutralizing antibodies to HIV","volume":"19","author":"Sok","year":"2018","journal-title":"Nat. Immunol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/nature10660","article-title":"Antibody-based protection against HIV infection by vectored immunoprophylaxis","volume":"481","author":"Balazs","year":"2011","journal-title":"Nature"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"3195","DOI":"10.1038\/s41467-020-16928-9","article-title":"Durable protection against repeated penile exposures to simian-human immunodeficiency virus by broadly neutralizing antibodies","volume":"11","author":"Garber","year":"2020","journal-title":"Nat. Commun"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1097\/COH.0000000000000556","article-title":"Neutralizing antibodies for HIV-1 prevention","volume":"14","author":"Julg","year":"2019","journal-title":"Curr. Opin. HIV AIDS"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.chom.2019.08.014","article-title":"A Meta-analysis of Passive Immunization Studies Shows that Serum-Neutralizing Antibody Titer Associates with Protection against SHIV Challenge","volume":"26","author":"Pegu","year":"2019","journal-title":"Cell Host Microbe"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1084\/jem.20132494","article-title":"Passive transfer of modest titers of potent and broadly neutralizing anti-HIV monoclonal antibodies block SHIV infection in macaques","volume":"211","author":"Shingai","year":"2014","journal-title":"J. Exp. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1038\/s41591-018-0186-4","article-title":"Safety and antiviral activity of combination HIV-1 broadly neutralizing antibodies in viremic individuals","volume":"24","author":"Gruell","year":"2018","journal-title":"Nat. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/s41591-019-0412-8","article-title":"Broadly neutralizing anti-HIV-1 monoclonal antibodies in the clinic","volume":"25","author":"Caskey","year":"2019","journal-title":"Nat. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/s41586-018-0531-2","article-title":"Combination therapy with anti-HIV-1 antibodies maintains viral suppression","volume":"561","author":"Mendoza","year":"2018","journal-title":"Nature"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/nature11604","article-title":"HIV therapy by a combination of broadly neutralizing antibodies in humanized mice","volume":"492","author":"Klein","year":"2012","journal-title":"Nature"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Gilbert, P.B., Juraska, M., deCamp, A.C., Karuna, S., Edupuganti, S., Mgodi, N., Donnell, D.J., Bentley, C., Sista, N., and Andrew, P. (2017). Basis and Statistical Design of the Passive HIV-1 Antibody Mediated Prevention (AMP) Test-of-Concept Efficacy Trials. Stat. Commun. Infect. Dis., 9.","DOI":"10.1515\/scid-2016-0001"},{"key":"ref_23","unstructured":"National Institutes of Health (NIH), U.S, and National Library of Medicine (2020, November 10). Clinical Trials, Available online: https:\/\/www.clinicaltrials.gov."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Morris, G.C., Wiggins, R.C., Woodhall, S.C., Bland, J.M., Taylor, C.R., Jespers, V., Vcelar, B.A., and Lacey, C.J. (2014). MABGEL 1: First phase 1 trial of the anti-HIV-1 monoclonal antibodies 2F5, 4E10 and 2G12 as a vaginal microbicide. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0116153"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Muyldermans, S. (2020). Generation and design of nanobodies. FEBS J.","DOI":"10.1111\/febs.15515"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s00430-009-0116-7","article-title":"Single domain antibodies: Promising experimental and therapeutic tools in infection and immunity","volume":"198","author":"Wesolowski","year":"2009","journal-title":"Med. Microbiol. Immunol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"250","DOI":"10.3389\/fimmu.2014.00250","article-title":"Immunologic Basis for Long HCDR3s in Broadly Neutralizing Antibodies Against HIV-1","volume":"5","author":"Yu","year":"2014","journal-title":"Front. Immunol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1084\/jem.20112655","article-title":"Potent and broad neutralization of HIV-1 by a llama antibody elicited by immunization","volume":"209","author":"McCoy","year":"2012","journal-title":"J. Exp. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"8390","DOI":"10.1038\/s41598-017-08273-7","article-title":"Selection of nanobodies with broad neutralizing potential against primary HIV-1 strains using soluble subtype C gp140 envelope trimers","volume":"7","author":"Koch","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1111\/1574-6976.12029","article-title":"Vaginal microbiota and its role in HIV transmission and infection","volume":"37","author":"Petrova","year":"2013","journal-title":"FEMS Microbiol. Rev."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Welch, J.L., Xiang, J., Okeoma, C.M., Schlievert, P.M., and Stapleton, J.T. (2020). Glycerol Monolaurate, an Analogue to a Factor Secreted by Lactobacillus, Is Virucidal against Enveloped Viruses, Including HIV-1. mBio, 11.","DOI":"10.1128\/mBio.00686-20"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.immuni.2016.12.013","article-title":"Lactobacillus-Deficient Cervicovaginal Bacterial Communities Are Associated with Increased HIV Acquisition in Young South African Women","volume":"46","author":"Gosmann","year":"2017","journal-title":"Immunity"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.jri.2007.02.002","article-title":"The genital tract immune milieu: An important determinant of HIV susceptibility and secondary transmission","volume":"77","author":"Kaul","year":"2008","journal-title":"J. Reprod. Immunol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"5784","DOI":"10.1128\/AEM.00945-15","article-title":"An Exopolysaccharide-Deficient Mutant of Lactobacillus rhamnosus GG Efficiently Displays a Protective Llama Antibody Fragment against Rotavirus on Its Surface","volume":"81","author":"Alvarez","year":"2015","journal-title":"Appl. Environ. Microbiol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1128\/IAI.00870-15","article-title":"Neutralization of Clostridium Difficile Toxin B Mediated by Engineered Lactobacilli That Produce Single-Domain Antibodies","volume":"84","author":"Andersen","year":"2016","journal-title":"Infect. Immun."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"11672","DOI":"10.1073\/pnas.1934747100","article-title":"Inhibition of HIV infectivity by a natural human isolate of Lactobacillus jensenii engineered to express functional two-domain CD4","volume":"100","author":"Chang","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Gunaydin, G., Alvarez, B., Lin, Y., Hammarstrom, L., and Marcotte, H. (2014). Co-expression of anti-rotavirus proteins (llama VHH antibody fragments) in Lactobacillus: Development and functionality of vectors containing two expression cassettes in tandem. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0096409"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1038\/nbt0702-702","article-title":"In situ delivery of passive immunity by lactobacilli producing single-chain antibodies","volume":"20","author":"Kruger","year":"2002","journal-title":"Nat. Biotechnol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1038\/mi.2011.30","article-title":"Prevention of vaginal SHIV transmission in macaques by a live recombinant Lactobacillus","volume":"4","author":"Lagenaur","year":"2011","journal-title":"Mucosal Immunol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"3250","DOI":"10.1128\/AAC.00493-06","article-title":"Engineered vaginal lactobacillus strain for mucosal delivery of the human immunodeficiency virus inhibitor cyanovirin-N","volume":"50","author":"Liu","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1089\/aid.2015.0378","article-title":"Expression of Human Immunodeficiency Virus Type 1 Neutralizing Antibody Fragments Using Human Vaginal Lactobacillus","volume":"32","author":"Marcobal","year":"2016","journal-title":"AIDS Res. Hum. Retrovir."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2174","DOI":"10.1128\/AEM.02690-10","article-title":"Integrative expression system for delivery of antibody fragments by lactobacilli","volume":"77","author":"Martin","year":"2011","journal-title":"Appl. Environ. Microbiol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1086\/508747","article-title":"Lactobacilli expressing variable domain of llama heavy-chain antibody fragments (lactobodies) confer protection against rotavirus-induced diarrhea","volume":"194","author":"Pant","year":"2006","journal-title":"J. Infect. Dis."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/mi.2009.116","article-title":"Orally administered L. lactis secreting an anti-TNF Nanobody demonstrate efficacy in chronic colitis","volume":"3","author":"Vandenbroucke","year":"2010","journal-title":"Mucosal Immunol."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Larsson, P.G., Brandsborg, E., Forsum, U., Pendharkar, S., Andersen, K.K., Nasic, S., Hammarstrom, L., and Marcotte, H. (2011). Extended antimicrobial treatment of bacterial vaginosis combined with human lactobacilli to find the best treatment and minimize the risk of relapses. BMC Infect. Dis., 11.","DOI":"10.1186\/1471-2334-11-223"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.micres.2017.08.003","article-title":"Characterization and complete genome sequences of L. rhamnosus DSM 14870 and L. gasseri DSM 14869 contained in the EcoVag((R)) probiotic vaginal capsules","volume":"205","author":"Marcotte","year":"2017","journal-title":"Microbiol. Res."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Marcotte, H., Larsson, P.G., Andersen, K.K., Zuo, F., Mikkelsen, L.S., Brandsborg, E., Gray, G., Laher, F., and Otwombe, K. (2019). An exploratory pilot study evaluating the supplementation of standard antibiotic therapy with probiotic lactobacilli in south African women with bacterial vaginosis. BMC Infect. Dis., 19.","DOI":"10.1186\/s12879-019-4425-1"},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Pendharkar, S., Brandsborg, E., Hammarstrom, L., Marcotte, H., and Larsson, P.G. (2015). Vaginal colonisation by probiotic lactobacilli and clinical outcome in women conventionally treated for bacterial vaginosis and yeast infection. BMC Infect. Dis., 15.","DOI":"10.1186\/s12879-015-0971-3"},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Sanders, R.W., Derking, R., Cupo, A., Julien, J.P., Yasmeen, A., de Val, N., Kim, H.J., Blattner, C., de la Pena, A.T., and Korzun, J. (2013). A next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies. PLoS Pathog., 9.","DOI":"10.1371\/journal.ppat.1003618"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1006\/plas.2001.1531","article-title":"Construction of compatible wide-host-range shuttle vectors for lactic acid bacteria and Escherichia coli","volume":"46","author":"Zuniga","year":"2001","journal-title":"Plasmid"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/978-1-59745-170-3_26","article-title":"Measuring HIV neutralization in a luciferase reporter gene assay","volume":"485","author":"Montefiori","year":"2009","journal-title":"Methods Mol. Biol. (Clifton N.J.)"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.virol.2006.10.005","article-title":"Double-labelled HIV-1 particles for study of virus-cell interaction","volume":"360","author":"Lampe","year":"2007","journal-title":"Virology"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"6332","DOI":"10.1128\/JVI.76.12.6332-6343.2002","article-title":"Envelope-dependent, cyclophilin-independent effects of glycosaminoglycans on human immunodeficiency virus type 1 attachment and infection","volume":"76","author":"Zhang","year":"2002","journal-title":"J. Virol."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Vanshylla, K., Held, K., Eser, T.M., Gruell, H., Jain, K., Weiland, D., Muench, J., Gruettner, B., Geldmacher, C., and Klein, F. (2020). A novel humanized mouse model to study mucosal HIV-1 transmission and prevention. BioRxiv, 2020.","DOI":"10.1101\/2020.08.31.274167"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"4531","DOI":"10.1128\/JCM.41.10.4531-4536.2003","article-title":"New real-time reverse transcriptase-initiated PCR assay with single-copy sensitivity for human immunodeficiency virus type 1 RNA in plasma","volume":"41","author":"Palmer","year":"2003","journal-title":"J. Clin. Microbiol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1128\/MMBR.63.1.174-229.1999","article-title":"Surface proteins of gram-positive bacteria and mechanisms of their targeting to the cell wall envelope","volume":"63","author":"Navarre","year":"1999","journal-title":"Microbiol. Mol. Biol. Rev."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1002\/(SICI)1097-0282(199807)46:1<39::AID-BIP4>3.0.CO;2-Z","article-title":"The interactions between the fluorescent dye thiazole orange and DNA","volume":"46","author":"Nygren","year":"1998","journal-title":"Biopolymers"},{"key":"ref_58","first-page":"28","article-title":"Lectins, adhesins, and lectin-like substances of lactobacilli and bifidobacteria","volume":"1","author":"Lakhtin","year":"2006","journal-title":"Vestn. Ross. Akad. Med. Nauk"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s12977-018-0455-9","article-title":"Antibody-mediated prevention and treatment of HIV-1 infection","volume":"15","author":"Gruell","year":"2018","journal-title":"Retrovirology"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1038\/nri.2017.148","article-title":"Passive immunotherapy of viral infections: \u2018super-antibodies\u2019 enter the fray","volume":"18","author":"Walker","year":"2018","journal-title":"Nat. Rev. Immunol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/cei.12692","article-title":"Safety, pharmacokinetics and neutralization of the broadly neutralizing HIV-1 human monoclonal antibody VRC01 in healthy adults","volume":"182","author":"Ledgerwood","year":"2015","journal-title":"Clin. Exp. Immunol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s12977-018-0449-7","article-title":"Adeno-associated virus gene delivery of broadly neutralizing antibodies as prevention and therapy against HIV-1","volume":"15","author":"Lin","year":"2018","journal-title":"Retrovirology"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.immuni.2019.02.005","article-title":"Adeno-Associated Virus Delivery of Anti-HIV Monoclonal Antibodies Can Drive Long-Term Virologic Suppression","volume":"50","author":"Fuchs","year":"2019","journal-title":"Immunity"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"e230","DOI":"10.1016\/S2352-3018(19)30003-7","article-title":"Adeno-associated virus vectored immunoprophylaxis to prevent HIV in healthy adults: A phase 1 randomised controlled trial","volume":"6","author":"Priddy","year":"2019","journal-title":"Lancet HIV"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.omtm.2019.06.002","article-title":"AAV-Mediated Expression of Broadly Neutralizing and Vaccine-like Antibodies Targeting the HIV-1 Envelope V2 Region","volume":"14","author":"Makoah","year":"2019","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"16068","DOI":"10.1038\/mtm.2016.68","article-title":"Promise and problems associated with the use of recombinant AAV for the delivery of anti-HIV antibodies","volume":"3","author":"Fuchs","year":"2016","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.ymthe.2019.01.004","article-title":"Anti-drug Antibody Responses Impair Prophylaxis Mediated by AAV-Delivered HIV-1 Broadly Neutralizing Antibodies","volume":"27","author":"Gardner","year":"2019","journal-title":"Mol. Ther."},{"key":"ref_68","unstructured":"(2020, November 10). Ablynx Clinical Programs. Available online: www.ablynx.com."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s12265-012-9435-y","article-title":"Novel antiplatelet agents: ALX-0081, a Nanobody directed towards von Willebrand factor","volume":"6","author":"Bartunek","year":"2013","journal-title":"J. Cardiovasc. Transl. Res."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1002\/ijc.10212","article-title":"Efficient tumor targeting by single-domain antibody fragments of camels","volume":"98","author":"Lauwereys","year":"2002","journal-title":"Int. J. Cancer"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s40259-019-00392-z","article-title":"The Therapeutic Potential of Nanobodies","volume":"34","author":"Jovcevska","year":"2020","journal-title":"BioDrugs"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/j.drudis.2016.04.003","article-title":"Nanobodies as therapeutics: Big opportunities for small antibodies","volume":"21","author":"Steeland","year":"2016","journal-title":"Drug Discov. Today"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1182\/blood-2010-11-317859","article-title":"Antithrombotic drug candidate ALX-0081 shows superior preclinical efficacy and safety compared with currently marketed antiplatelet drugs","volume":"118","author":"Ulrichts","year":"2011","journal-title":"Blood"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1007\/s00280-015-2712-0","article-title":"Unexpected hepatotoxicity in a phase I study of TAS266, a novel tetravalent agonistic Nanobody(R) targeting the DR5 receptor","volume":"75","author":"Papadopoulos","year":"2015","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"5627","DOI":"10.4049\/jimmunol.176.9.5627","article-title":"Lactobacilli-expressed single-chain variable fragment (scFv) specific for intercellular adhesion molecule 1 (ICAM-1) blocks cell-associated HIV-1 transmission across a cervical epithelial monolayer","volume":"176","author":"Chancey","year":"2006","journal-title":"J. Immunol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"2994","DOI":"10.1128\/AAC.01492-09","article-title":"Engineering of Lactobacillus jensenii to secrete RANTES and a CCR5 antagonist analogue as live HIV-1 blockers","volume":"54","author":"Vangelista","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Brichacek, B., Lagenaur, L.A., Lee, P.P., Venzon, D., and Hamer, D.H. (2013). In vivo evaluation of safety and toxicity of a Lactobacillus jensenii producing modified cyanovirin-N in a rhesus macaque vaginal challenge model. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0078817"},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Petrova, M.I., Imholz, N.C., Verhoeven, T.L., Balzarini, J., Van Damme, E.J., Schols, D., Vanderleyden, J., and Lebeer, S. (2016). Lectin-Like Molecules of Lactobacillus rhamnosus GG Inhibit Pathogenic Escherichia coli and Salmonella Biofilm Formation. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0161337"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/0264-410X(95)00019-W","article-title":"Efficient purification and rigorous characterisation of a recombinant gp120 for HIV vaccine studies","volume":"13","author":"Jones","year":"1995","journal-title":"Vaccine"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1038\/s41598-018-37120-6","article-title":"Isolation and characterization of Lactobacillus-derived membrane vesicles","volume":"9","author":"Dean","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"5656","DOI":"10.1038\/s41467-019-13468-9","article-title":"Extracellular vesicles from symbiotic vaginal lactobacilli inhibit HIV-1 infection of human tissues","volume":"10","author":"Vanpouille","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1021\/acssynbio.9b00114","article-title":"Inducible Plasmid Self-Destruction (IPSD) Assisted Genome Engineering in Lactobacilli and Bifidobacteria","volume":"8","author":"Zuo","year":"2019","journal-title":"ACS Synth. Biol."}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/8\/4\/758\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:44:36Z","timestamp":1760179476000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/8\/4\/758"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,13]]},"references-count":82,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["vaccines8040758"],"URL":"https:\/\/doi.org\/10.3390\/vaccines8040758","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,13]]}}}